OCUPHIRE PHARMA INC. - COMMON STOCK

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

06 يونيو 2024 06:57:22 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

10 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

06 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma to Present at the Aegis Virtual Conference

03 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

22 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

11 أبريل 2024 09:03:48 بحسب Nasdaq GlobeNewswire

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

01 أبريل 2024 06:14:52 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

08 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

23 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 فبراير 2024 15:10:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

14 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

05 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 يناير 2024 15:10:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

04 يناير 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

30 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27 نوفمبر 2023 15:38:14 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

27 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

13 نوفمبر 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy

02 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2023 15:52:46 بحسب Nasdaq GlobeNewswire